-
Sri Lanka's de Silva quits as Test captain
-
Oil prices surge and stocks sink on fresh inflation worries
-
Alcaraz feeling 'mentally fresh' ahead of Shanghai return
-
AI startup Manus raises $500m after Meta acquisition blocked by China
-
Israel drastically reduces British diplomatic presence in Jerusalem
-
From refuge to repatriations: Malaysia's Myanmar U-turn
-
Stocks fall further as oil surge fans fresh inflation worries
-
Morikawa says LIV players face 'business decision' after Rahm exit
-
North Korea demands South show 'utmost respect' to restore relations
-
Tenzing Norgay's son says Himalayas sending climate warning
-
Saudi says three dead in airport attacks claimed by Houthis
-
On your bike! Bottas opts for two wheels to reach Singapore GP
-
'Mad dream': New showcase for African film opens in London
-
Alcaraz, Sinner, Osaka commit to Australian Open '1 Point Slam'
-
All Blacks coach Rennie says Wallabies exit 'part of the game'
-
Dodgers beat Braves to advance in MLB playoffs, Rays oust Yankees
-
The growing protests against India's poll body - and PM Modi
-
'A sun as black as my lungs': how corruption crucified a polluted Albania city
-
Stocks fall further as oil spike fans fresh inflation worries
-
The British historian helping the French rediscover de Gaulle
-
Bad COP, worse COP? EU tempers hopes for UN climate summit
-
Dodgers beat Braves to advance, Guardians survive in MLB playoffs
-
Rookie Henry named in Wallabies midfield to face All Blacks
-
Latin American, Caribbean women top Nobel literature buzz
-
Housing crisis set to dominate Spain's snap election
-
US says Fiji-based Chinese official paid bribes for Beijing
-
Gas, health care, utilities: high costs squeeze US midterm voters
-
After botched US execution, Christa Pike was nearly taken off life support
-
New Zealand Rugby seeks injunction over PNG Chiefs name
-
Guinea-Bissau junta urges military unit loyal to ex-president to disarm
-
Samsung expects 780% quarterly operating profit jump on AI boom
-
As species decline, green turtles offer glimmer of hope
-
Guardians survive with 9-3 win over White Sox
-
Brothers Scott and Beauden Barrett named to start for All Blacks
-
Saudi Arabia says 3 dead at airports after Houthis claim attacks
-
EU trade chief seeks to dial down China tensions
-
Stocks slide as oil sees volatile trading day over Iran war fears
-
'Never again Bolsonaro': thousands march ahead of Brazil election runoff
-
Microsoft pushes AI vision with new, expensive Surface laptop
-
After botched execution, US woman was nearly taken off life support before revival
-
Five children among 28 killed in Russian strikes on Ukraine
-
Searing AIDS drama 'Elsinore' opens London film festival
-
Odell Beckham Jr signs with Minnesota Vikings
-
Evicted pensioner who sparked Spain housing protests dies: tenant union
-
Saudi Arabia says three dead at airports after Houthis claim attacks
-
Golf star Rahm quitting LIV tour over 'unacceptable' terms
-
Trump plans to turn Florida golf course into presidential retreat
-
Thousands march fearing return of a Bolsonaro presidency in Brazil
-
WHO says cannot conduct full risk assessment on Russia plague reports
-
French PM denies police ordered to confront student protesters
Twitter prank spurs unexpected scrutiny of insulin prices
A Twitter imposter cost a US pharmaceutical giant billions of dollars, but the viral prank triggered another unexpected crisis -- a new wave of scrutiny of the high cost of its insulin.
Authentic-looking fake accounts proliferated last week after Twitter rolled out a paid verification service, the latest in a string of chaotic developments since Elon Musk's blockbuster $44 billion buyout of the influential platform.
Among the victims was drugmaker Eli Lilly, whose stock price nosedived -- erasing billions in market capitalization -- after a parody account stamped with a verification tag purchased for $8 tweeted that insulin was being made available for free.
The company was forced to issue an apology for the "misleading message from a fake Lily account," but the disinformation stirred fresh attention to a long-festering debate about high insulin prices.
"What you should *actually* apologize for is price gouging life-saving insulin," tweeted Chicago-based human rights lawyer Qasim Rashid.
"People are dying because of your greed (and) cruelty. Apologize for that."
Gaining traction alongside such comments was a cartoon meme with a half-elephant, half-human character riling up people to be more upset about the price of insulin than the price of gas.
"Fake Eli Lilly might be offering something closer to truth than real Eli Lilly," Peter Maybarduk, from the nonprofit Public Citizen, told AFP.
"Parody is successful when it reveals embarrassing and widely understood truth."
- 'Abusive pricing' -
In recent decades, insulin prices have soared in the United States, costing more than eight times more than in 32 comparable high-income countries, according to a 2020 Rand Corporation study.
A survey released in October by the nonprofit T1International showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
On Monday, which marks World Diabetes Day, dozens of advocacy groups including Public Citizen sent a letter to Congress demanding a stop to what they called insulin price-gouging.
"There's no defense for Eli Lilly's abusive insulin pricing," said Maybarduk.
"It's long past time we provide access to insulin for all, and yes –- it should be free," he added.
The backlash against Eli Lilly showcased the real-life potential of online disinformation to trigger chaos and financial loss. The company's stock price has marginally recovered since last week's drop.
But in this rare instance, it brought to the fore a much-ignored public health issue.
- 'Panic' -
"The disinformation is not without ramification -- Eli Lilly's stock price dropped dramatically," Al Tompkins, a senior faculty member at the Poynter Institute, told AFP.
But exploiting Twitter's chaotic rollout of its paid verification policy, the prank managed to make "the insulin drug price conversation relevant to a lot of people."
On Friday, Twitter disabled sign-ups for the contentious feature known as Twitter Blue, with reports saying it had been temporarily disabled to help address impersonation issues -- but not before several brands took a hit.
Shares of other firms such as aerospace defence company Lockheed Martin also took a hit after being targeted by impersonators.
The prank sparked panic inside Eli Lilly, with officials scrambling to contact Twitter representatives to take it down, but the platform did not react for hours, the Washington Post reported on Monday.
By Friday, Eli Lilly executives ordered a halt to all ad campaigns on Twitter, a move that could potentially cost the platform millions of dollars.
That would mark another blow to Twitter, which laid off nearly half its workforce after Musk's takeover as it struggles to boost revenue.
Eli Lilly and Twitter did not respond to AFP's request for comment.
C.Meier--BTB